Table 1.
Patient characteristics stratified by HIV RNA viral load at INSTI initiation.
| Characteristic at INSTI initiation | Viral Load ≥50 (N=327) |
Viral Load <50 (N=446) |
P1 |
|---|---|---|---|
| N (%) or median (IQR) | N (%) or median (IQR) | ||
| Sexual risk group | 0.58 | ||
| MSM | 137 (42%) | 198 (44%) | |
| Women | 104 (32%) | 145 (33%) | |
| Heterosexual men | 86 (26%) | 103 (23%) | |
| IDU | 29 (9%) | 49 (11%) | 0.40 |
| Race/ethnicity | <0.05 | ||
| African American | 207 (63%) | 243 (54%) | |
| White | 88 (27%) | 161 (36%) | |
| Hispanic/other | 32 (10%) | 42 (9%) | |
| Age, years | 44 (35, 50) | 50 (41, 56) | <0.01 |
| Calendar year | 2012 (2009, 2014) | 2014 (2013, 2015) | <0.01 |
| Years since first ART | 9 (4, 13) | 11 (5, 16) | <0.01 |
| Prior ARV drugs | 6 (4, 9) | 5 (4, 8) | <0.05 |
| Prior ART regimens | 4 (2, 7) | 3 (1, 6) | <0.01 |
| Nadir CD4 count, cells/μL | 81 (15, 240) | 157 (48, 304) | <0.01 |
| CD4 count, cells/μL | 288 (113, 495) | 636 (443, 839) | <0.01 |
| HIV RNA, log10 copies/mL | 4.24 (2.98, 4.94) | N/A | N/A |
| Last prior regimen anchor class | <0.01 | ||
| NNRTI | 107 (33%) | 183 (41%) | |
| PI | 179 (55%) | 232 (52%) | |
| NNRTI and PI | 11 (3%) | 15 (3%) | |
| EI2 | 12 (4%) | 7 (2%) | |
| Other | 18 (5%) | 9 (2%) | |
| First INSTI regimen | <0.01 | ||
| EVG/COBI with ≥2 NRTI | 64 (20%) | 175 (39%) | |
| DTG with ≥2 NRTI | 61 (19%) | 141 (32%) | |
| RAL with ≥2 NRTI | 65 (20%) | 66 (15%) | |
| RAL with PI3 | 70 (21%) | 31 (7%) | |
| Other4 | 67 (20%) | 33 (7%) |
Abbreviations. ART: antiretroviral therapy. ARV: antiretroviral. COBI: cobicistat. DTG: dolutegravir. EI: entry inhibitor. EVG: elvitegravir. IDU: injection drug use. INSTI: integrase strand transfer inhibitor. IQR: interquartile range. MSM: men who have sex with men. PI: protease inhibitor. N/A: not applicable. NNRTI: non-nucleoside analog reverse transcriptase inhibitor. NRTI: nucleoside analog reverse transcriptase inhibitor. RAL: raltegravir. VL: viral load.
P value from Fisher’s Exact test for categorical variables and the Wilcoxon Rank-Sum test for continuous variables.
May include another anchor drug.
With or without any NRTI agent.
Includes patients on RAL in combination with an NNRTI (17 with VL≥50 and 14 with VL<50), RAL with a PI and an NNRTI (27 with VL≥50 and 7 with VL<50), RAL with an EI (15 with VL≥50 and 0 with VL<50), and DTG with another anchor agent (8 with VL≥50 and 12 with VL<50), all with or without any NRTI agent.